{"id":1437,"date":"2019-07-19T11:37:49","date_gmt":"2019-07-19T11:37:49","guid":{"rendered":"https:\/\/blogs.bmj.com\/spcare\/?p=1437"},"modified":"2019-07-19T11:37:49","modified_gmt":"2019-07-19T11:37:49","slug":"news-and-updates-from-www-palliativedrugs-com-107","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/spcare\/2019\/07\/19\/news-and-updates-from-www-palliativedrugs-com-107\/","title":{"rendered":"News and updates from www.palliativedrugs.com"},"content":{"rendered":"<p><b><i>Selected items from the News and Latest Additions sections of <\/i><\/b><a href=\"http:\/\/www.palliativedrugs.com\"><b><i>www.palliativedrugs.com<\/i><\/b><\/a><b><i>, the world\u2019s leading palliative care website with over 30,000 members from 169 Countries.<\/i><\/b><\/p>\n<h3>Hot topics<\/h3>\n<p><b>WHO guidelines for treatment of cancer pain published<\/b><\/p>\n<p><span style=\"font-weight: 400\">The World Health Organisation (WHO) has published \u2018Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. For more information, <\/span><a href=\"https:\/\/www.who.int\/ncds\/management\/palliative-care\/cancer-pain-guidelines\/en\/\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.\u00a0<\/span><\/p>\n<p><b>WHO discontinues two pain management guidelines<\/b><\/p>\n<p><span style=\"font-weight: 400\">WHO is discontinuing the following two guidelines in light of new scientific evidence that has emerged since the time of their publication and to address issues of conflicts of interest of the experts that have been raised:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Ensuring balance in national policies on controlled substances: Guidance for availability and accessibility of controlled medicines (2011)<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses (2012).<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400\">For more information, <\/span><a href=\"https:\/\/www.who.int\/medicines\/areas\/quality_safety\/guide_on_pain\/en\/\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b>Safer management of controlled drugs<\/b><\/p>\n<p><span style=\"font-weight: 400\">The annual report on the safer management of controlled drugs for 2018 has been published by the Care Quality Commission. As part of the recommendations, all health professionals are reminded of their responsibility to speak up on areas of concern that might negatively affect patient safety, including prescribing, administering, dispensing, supplying and disposing of controlled drugs. For more information, <\/span><a href=\"https:\/\/www.cqc.org.uk\/sites\/default\/files\/20190708_controlleddrugs2018_report.pdf\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b>Valproate further prescribing resources<\/b><\/p>\n<p><span style=\"font-weight: 400\">The following resources are available to support the prescribing of valproate in females of child-bearing potential. For more information on the risks of valproate in pregnancy, see our previous news item in <\/span><a href=\"https:\/\/www.palliativedrugs.com\/news\/april\/mhra-alert-valproate-updated-contra-indications.html\"><span style=\"font-weight: 400\">April 2018<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b><i>Pan college guidance<\/i><\/b><\/p>\n<p><span style=\"font-weight: 400\">This has been produced by experts from 13 national healthcare bodies, including Royal Colleges and the Royal Pharmaceutical Society for use in the authorised indications of epilepsy and bipolar disorders. It advises on the more challenging issues that health professionals in primary and specialist care might encounter in daily practice, e.g. transition from paediatric to adult services, competence to consent to treatment, and confidentiality. For more information, <\/span><a href=\"https:\/\/www.rpharms.com\/Portals\/0\/RPS%20document%20library\/Open%20access\/Support\/Guidance%20Document%20on%20Valproate.pdf?ver=2019-03-29-113144-853\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b><i>NICE summary<\/i><\/b><\/p>\n<p><span style=\"font-weight: 400\">NICE has produced a summary of their guidance and safety advice for valproate, including for off-label indications. For more information, <\/span><a href=\"https:\/\/www.nice.org.uk\/guidance\/cg137\/resources\/valproate-in-children-young-people-and-adults-summary-of-nice-guidance-and-safety-advice-pdf-6723784045\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b><i>Paediatric guidance<\/i><\/b><\/p>\n<p><span style=\"font-weight: 400\">The British Paediatric Neurology Association (BPNA) and the Royal College of Paediatrics and Child Health (RCPCH) have developed joint guidance about the use of valproate in female patients &lt;18 years. For more information, <\/span><a href=\"https:\/\/www.rcpch.ac.uk\/sites\/default\/files\/2019-04\/bpna_rcpch_valproate_guidance_130419_0.pdf\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b>Valproate updated annual risk acknowledgement form<\/b><\/p>\n<p><span style=\"font-weight: 400\">The <\/span><a href=\"https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/794114\/Valp-ARAF-March-2019.pdf\"><span style=\"font-weight: 400\">Annual Risk Acknowledgement Form<\/span><\/a><span style=\"font-weight: 400\">, used as part of the <\/span><a href=\"https:\/\/www.gov.uk\/drug-safety-update\/valproate-medicines-epilim-depakote-contraindicated-in-women-and-girls-of-childbearing-potential-unless-conditions-of-pregnancy-prevention-programme-are-met\"><span style=\"font-weight: 400\">Pregnancy Prevention Programme<\/span><\/a><span style=\"font-weight: 400\"> (PPP), for prescribing valproate to females of child-bearing potential has been updated following feedback from health professionals and stakeholders. This form should be used for all future reviews of female patients on valproate. For more information, <\/span><a href=\"https:\/\/www.gov.uk\/drug-safety-update\/valproate-medicines-and-serious-harms-in-pregnancy-new-annual-risk-acknowledgement-form-and-clinical-guidance-from-professional-bodies-to-support-compliance-with-the-pregnancy-prevention-programme\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b>NICE lung cancer guidance updated<\/b><\/p>\n<p><span style=\"font-weight: 400\">Updated NICE guidance, Lung cancer: diagnosis and management (NG122), has been published. It covers non-small-cell and small-cell lung cancer. The only changes to the palliative care section involve signposting to other relevant NICE guidance for bone metastases and skeletal-related events. For more information, <\/span><a href=\"https:\/\/www.nice.org.uk\/guidance\/ng122\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b>NICE consultation for end of life care service delivery<\/b><\/p>\n<p><span style=\"font-weight: 400\">Draft guidance, for end of life care service delivery, has been under consultation and is expected to be published in October 2019. For more information, <\/span><a href=\"https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-cgwave0799\/consultation\/html-content-2\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<h3>Drug updates<\/h3>\n<p><b>Epistatus 10mg oromucosal solution SPC updated<\/b><\/p>\n<p><span style=\"font-weight: 400\">Information has been added to the SPC regarding the risk of use of Epistatus (midazolam) 10mg oromucosal solution in hepatic impairment: Because hepatic impairment reduces the clearance of midazolam and increases the terminal half-life, the clinical effects may be stronger and prolonged. Note. Epistatus is contra-indicated in patients with severe hepatic impairment.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Warnings regarding the CNS depressant risks of the concurrent use of opioids have also been added. For more information, <\/span><a href=\"https:\/\/www.medicines.org.uk\/emc\/product\/2679\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<h3>Latest Additions<\/h3>\n<p><b>Better treatments for breathlessness in palliative care and end of life<\/b><\/p>\n<p><span style=\"font-weight: 400\">The recently launched, EU funded BETTER-B project are seeking the views of <\/span><i><span style=\"font-weight: 400\">physicians in respiratory and palliative medicine<\/span><\/i><span style=\"font-weight: 400\"> on the management of chronic breathlessness for patients with severe chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and lung cancer. We encourage our members to complete the survey, which takes approximately 10\u221215minutes. The survey will close at the end of July 2019. Click <\/span><a href=\"https:\/\/www.smartsurvey.co.uk\/s\/F3J2M\/\"><span style=\"font-weight: 400\">here<\/span><\/a><span style=\"font-weight: 400\">, to learn more and complete the survey.<\/span><\/p>\n<p><b>NSAIDs \u2013 What do you use?<\/b><\/p>\n<p><span style=\"font-weight: 400\">Results are available from our survey on the use of Non-Steroidal Anti-inflammatory drugs (NSAIDs). For more information, <\/span><a href=\"https:\/\/www.palliativedrugs.com\/latest.html\"><span style=\"font-weight: 400\">click here<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b>PCF updated monographs<\/b><\/p>\n<p><span style=\"font-weight: 400\">The on-line PCF is being continually updated. Some of the website monographs now supersede those in the print publication of the 6th edition of the Palliative Care Formulary (PCF6). During March to June 2019 the following monographs have been updated and can be accessed on the <\/span><a href=\"https:\/\/about.medicinescomplete.com\/publication\/palliative-care-formulary\/\"><span style=\"font-weight: 400\">MedicinesComplete<\/span><\/a><span style=\"font-weight: 400\"> website:<\/span><\/p>\n<p><span style=\"font-weight: 400\">Chapter 01: Topical products for haemorrhoids<\/span><\/p>\n<p><span style=\"font-weight: 400\">Chapter 02: Furosemide, Haemostatics, Spironolactone<\/span><\/p>\n<p><span style=\"font-weight: 400\">Chapter 04: Gabapentin and pregabalin (minor change), Valproate (minor change)<\/span><\/p>\n<p><span style=\"font-weight: 400\">Chapter 05: QCG: Use of transdermal fentanyl patches (minor change), QCG: Use of buprenorphine transdermal patches (minor change)<\/span><\/p>\n<p><span style=\"font-weight: 400\">Chapter 07: Bisphosphonates (minor change), Desmopressin, Danazol, Progestogens<\/span><\/p>\n<p><span style=\"font-weight: 400\">Chapter 08: Tamsulosin, Urinary antimuscarinics (previously oxybutynin)<\/span><\/p>\n<p><span style=\"font-weight: 400\">Chapter 18: Hepatic impairment<\/span><\/p>\n<p><span style=\"font-weight: 400\">Chapter 30: Transdermal patches (minor change).<\/span><\/p>\n<p><span style=\"font-weight: 400\">A full list of all the monographs updated since the publication of PCF6 can be found on the <\/span><a href=\"https:\/\/www.palliativedrugs.com\/latest.html\"><span style=\"font-weight: 400\">Latest additions<\/span><\/a><span style=\"font-weight: 400\"> section of the www.palliativedrugs.com website, along with more details of the minor updates. In addition, follow @palliativedrugs on twitter for the latest updates.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400\">Prepared by Sarah Charlesworth and Andrew Wilcock<\/span><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world\u2019s leading palliative care website with over 30,000 members from 169 Countries. Hot topics WHO guidelines for treatment of cancer pain published The World Health Organisation (WHO) has published \u2018Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/spcare\/2019\/07\/19\/news-and-updates-from-www-palliativedrugs-com-107\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":357,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2833],"tags":[],"class_list":["post-1437","post","type-post","status-publish","format-standard","hentry","category-updates-from-www-palliativedrugs-com"],"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/1437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/users\/357"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/comments?post=1437"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/1437\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/media?parent=1437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/categories?post=1437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/tags?post=1437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}